A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics

Abstract

Neurodegenerative disorders are primarily characterized by neuron loss. The most common neurodegenerative disorders include Alzheimer’s and Parkinson’s disease. Although there are several medicines currently approved for managing neurodegenerative disorders, a large majority of them only help with associated symptoms. This lack of pathogenesis-targeting therapies is primarily due to the restrictive effects of the blood–brain barrier (BBB), which keeps close to 99% of all “foreign substances” out of the brain. Since their discovery, nanoparticles have been successfully used for targeted delivery into many organs, including the brain. This review briefly describes the pathophysiology of Alzheimer’s, Parkinson’s disease, and amyotrophic lateral sclerosis, and their current management approaches. We then highlight the major challenges of brain-drug delivery, followed by the role of nanotherapeutics for the diagnosis and treatment of various neurological disorders.

References 146

1. 1.

   Merelli A., Czornyj L., Lazarowski A. Erythropoietin: A neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy. Curr. Pharm. Des. 2013;19:6791-6801.

   Not in our library10.2174/1381612811319380011

2. 2.

   Choonara Y.E., Pillay V., Du Toit L.C., Modi G., Naidoo D., Ndesendo V.M., Sibambo S.R. Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. Int. J. Mol. Sci. 2009;10:2510-2557.

   Not in our library10.3390/ijms10062510

3. 3.

   Rapp T., Chauvin P., Costa N., Molinier L. Health economic considerations in neurodegenerative disorders. Imaging Neurodegener. Disord. 2015;42.

   Not in our library10.1093/med/9780199671618.003.0004

4. 4.

   Harilal S., Jose J., Parambi D.G.T., Kumar R., Mathew G.E., Uddin M.S., Kim H., Mathew B. Advancements in nanotherapeutics for Alzheimer’s disease: Current perspectives. J. Pharm. Pharmacol. 2019;71:1370-1383.

   Not in our library10.1111/jphp.13132

5. 5.

   Hinge N.S., Kathuria H., Pandey M.M. Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer’s. Appl. Mater. Today. 2022;26:101303.

   Not in our library10.1016/j.apmt.2021.101303

6. 6.

   Montazersaheb S., Ahmadian E., Maleki Dizaj S., Jahanbani Y., Davaran S., Huseynova I., Zhdanov R., Keskin C., Khalilov R., Eftekhari A. Emerging Nanotherapeutic Strategies in Alzheimer’s Disease. Frontiers in Clinical Drug Research-Dementia. 2021;2:173.

   Not in our library

7. 7.

   Brain Basics: The Life and Death of a Neuron. 2002.

   Not in our library

8. 8.

   Van den Heuvel M.P., Sporns O. Network hubs in the human brain. Trends Cogn. Sci. 2013;17:683-696.

   Not in our library10.1016/j.tics.2013.09.012

9. 9.

   Kempermann G. Adult Neurogenesis: Stem Cells and Neuronal Development in the Adult Brain. 2006.

   Not in our library

10. 10.

    Pino A., Fumagalli G., Bifari F., Decimo I. New neurons in adult brain: Distribution, molecular mechanisms and therapies. Biochem. Pharmacol. 2017;141:4-22.

    Not in our library10.1016/j.bcp.2017.07.003

11. 11.

    Ganat Y.M., Silbereis J., Cave C., Ngu H., Anderson G.M., Ohkubo Y., Ment L.R., Vaccarino F.M. Early postnatal astroglial cells produce multilineage precursors and neural stem cells in vivo. J. Neurosci. 2006;26:8609-8621.

    Not in our library10.1523/jneurosci.2532-06.2006

12. 12.

    Przedborski S., Vila M., Jackson-Lewis V. Series Introduction: Neurodegeneration: What is it and where are we? J. Clin. Investig. 2003;111:3-10.

    Not in our library10.1172/jci200317522

13. 13.

    Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.-L. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067-1081.

    Not in our library10.1016/j.neuron.2010.11.030

14. 14.

    Milnerwood A.J., Raymond L.A. Early synaptic pathophysiology in neurodegeneration: Insights from Huntington’s disease. Trends Neurosci. 2010;33:513-523.

    Not in our library10.1016/j.tins.2010.08.002

15. 15.

    Scott D.A., Tabarean I., Tang Y., Cartier A., Masliah E., Roy S. A pathologic cascade leading to synaptic dysfunction in α-synuclein-induced neurodegeneration. J. Neurosci. 2010;30:8083-8095.

    Not in our library10.1523/jneurosci.1091-10.2010

16. 16.

    Kovacs G.G. Molecular pathology of neurodegenerative diseases: Principles and practice. J. Clin. Pathol. 2019;72:725-735.

    Not in our library10.1136/jclinpath-2019-205952

17. 17.

    Martin J.B. Molecular basis of the neurodegenerative disorders. N. Engl. J. Med. 1999;340:1970-1980.

    Not in our library10.1056/nejm199906243402507

18. 18.

    Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 2000;1:120-130.

    Not in our library10.1038/35040009

19. 19.

    Hague S., Klaffke S., Bandmann O. Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease. J. Neurol. Neurosurg. Psychiatry. 2005;76:1058-1063.

    Not in our library10.1136/jnnp.2004.060186

20. 20.

    Harding B.N., Kariya S., Monani U.R., Chung W.K., Benton M., Yum S.W., Tennekoon G., Finkel R.S. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J. Neuropathol. Exp. Neurol. 2015;74:15-24.

    Not in our library10.1097/nen.0000000000000144

21. 21.

    Klockgether T., Mariotti C., Paulson H.L. Spinocerebellar ataxia. Nat. Rev. Dis. Primers. 2019;5:1-21.

    Not in our library10.1038/s41572-019-0074-3

22. 22.

    Liu H., Hu Y., Zhang Y., Zhang H., Gao S., Wang L., Wang T., Han Z., Sun B.L., Liu G. Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer’s disease GWAS and self-report proxy phenotype GWAX. Alzheimer’s Res. Ther. 2022;14:17.

    Not in our library10.1186/s13195-022-00963-3

23. 23.

    Jain N., Chen-Plotkin A.S. Genetic modifiers in neurodegeneration. Curr. Genet. Med. Rep. 2018;6:11-19.

    Not in our library10.1007/s40142-018-0133-1

24. 24.

    Jain V., Baitharu I., Barhwal K., Prasad D., Singh S.B., Ilavazhagan G.J.C. Enriched environment prevents hypobaric hypoxia induced neurodegeneration and is independent of antioxidant signaling. Cell. Mol. Neurobiol. 2012;32:599-611.

    Not in our library10.1007/s10571-012-9807-5

25. 25.

    Esch T., Stefano G.B., Fricchione G.L., Benson H.J.N.L. The role of stress in neurodegenerative diseases and mental disorders. Neuro Endocrinol. Lett. 2002;23:199-208.

    Not in our library

26. 26.

    Allan S.M., Rothwell N.J. Inflammation in central nervous system injury. Philos. Trans. R. Soc. B Biol. Sci. 2003;358:1669-1677.

    Not in our library10.1098/rstb.2003.1358

27. 27.
    Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications · 2017

    No notice
28. 28.

    Brouwer-DudokdeWit A.C., Savenije A., Zoeteweij M.W., Maat-Kievit A., Tibben A. A hereditary disorder in the family and the family life cycle: Huntington disease as a paradigm. Fam. Process. 2002;41:677-692.

    Not in our library10.1111/j.1545-5300.2002.00677.x

29. 29.

    Bayer T.A., Wirths O. Intracellular accumulation of amyloid-Beta-a predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease. Front. Aging Neurosci. 2010;2:8.

    Not in our library10.3389/fnagi.2010.00008

30. 30.
    Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer’s Disease · 2019

    No notice
31. 31.

    Butterfield D.A., Griffin S., Munch G., Pasinetti G.M. Amyloid β-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer’s disease brain exists. J. Alzheimer’s Dis. 2002;4:193-201.

    Not in our library10.3233/jad-2002-4309

32. 32.

    Paula V.d.J.R.d., Guimarães F.M., Diniz B.S., Forlenza O.V. Neurobiological pathways to Alzheimer’s disease: Amyloid-beta, TAU protein or both? Dement. Neuropsychol. 2009;3:188-194.

    Not in our library10.1590/s1980-57642009dn30300003

33. 33.

    Mondragón-Rodríguez S., Perry G., Zhu X., Boehm J. Amyloid Beta and tau proteins as therapeutic targets for Alzheimer’s disease treatment: Rethinking the current strategy. Int. J. Alzheimer’s Dis. 2012;2012:1-7.

    Not in our library10.1155/2012/630182

34. 34.

    Spires-Jones T.L., Hyman B.T. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron. 2014;82:756-771.

    Not in our library10.1016/j.neuron.2014.05.004

35. 35.

    Akhondzadeh S., Noroozian M. Alzheimer’s disease: Pathophysiology and pharmacotherapy. IDrugs Investig. Drugs J. 2002;5:1062-1069.

    Not in our library

36. 36.

    Kouli A., Torsney K.M., Kuan W.-L. Parkinson’s disease: Etiology, neuropathology, and pathogenesis. Exon Publ. 2018;3-26.

    Not in our library10.15586/codonpublications.parkinsondisease.2018.ch1

37. 37.
    Interactions of pathological proteins in neurodegenerative diseases · 2017

    No notice
38. 38.

    Priyadarshi A., Khuder S.A., Schaub E.A., Priyadarshi S.S. Environmental risk factors and Parkinson’s disease: A metaanalysis. Environ. Res. 2001;86:122-127.

    Not in our library10.1006/enrs.2001.4264

39. 39.
    Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors · 2018

    No notice
40. 40.

    Gorell J.M., Peterson E.L., Rybicki B.A., Johnson C.C. Multiple risk factors for Parkinson’s disease. J. Neurol. Sci. 2004;217:169-174.

    Not in our library10.1016/j.jns.2003.09.014

Cited by papers we hold 4

• Multifunctional nanoparticle-mediated combining therapy for human diseases · 2024
  No notice
• The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets · 2024
  No notice
• Mitochondria and Brain Disease: A Comprehensive Review of Pathological Mechanisms and Therapeutic Opportunities · 2023
  No notice
• Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.